Biotech Late Stage Investors & VC Firms
652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.
T Capital Partners Co. Ltd.
TokyoGrowth–Late Stage$4B – $14B
3 people
Criteria Bio Ventures
BarcelonaSeed–Late Stage
7 people
Detong Capital
ShanghaiSeed–Late Stage$20M
11 people
Prospect Venture Partners
Menlo ParkSeed–Late Stage$3M – $5M
4 people
Sambrinvest
CharleroiSeries A–Late Stage
13 people
Sound Bioventures
MalmöSeed–Late Stage
9 people
Texas Ventures
HoustonSeed–Late Stage
6 people
JStar Capital Investments
AustinSeed–Late Stage
13 people
B-FLEXION
St. HelierSeed–Late Stage$500K
12 people
Finchley Healthcare Ventures
MontrealSeed–Late Stage
15 people
Radix Ventures
WarsawSeed–Late Stage$550K – $2.8M
10 people
AbCellera
VancouverSeries B–Late Stage
21 people
Soul Ventures
Series C–Late Stage
15 people
Blindspot Ventures Management Co
BostonPre-Seed–Late Stage
5 people
Invus
New YorkPre-Seed–Late Stage
8 people
DC Investment Partners
McLeanSeed–Late Stage$10M
10 people
Hike Capital
BeijingPre-Seed–Late Stage
8 people
Luma Group
New YorkSeed–Late Stage
13 people
Global BioAccess Fund
New YorkSeries A–Late Stage$10M
11 people
BioStar Capital
CharlevoixSeed–Late Stage$250K – $3M
10 people
Panakes Partners
MilanSeed–Late Stage
13 people
Amgen Ventures
Thousand OaksSeed–Late Stage$1M – $3M
6 people
Endeavour Vision
GenevaLate Stage
6 people
Amplitude Venture Capital
MontrealSeed–Late Stage
14 people
Related lists
Late Stage Investors & VC Firms (2974)Biotech Investors & VC Firms (2185)Biotech Seed Investors & VC Firms (1824)Late Stage Investors & VC Firms in North America (1695)Biotech Series A Investors & VC Firms (1668)Late Stage Investors & VC Firms in United States (1516)Biotech Investors & VC Firms in North America (1391)Biotech Investors & VC Firms in United States (1267)Late Stage Investors & VC Firms in Europe (965)Biotech Pre-Seed Investors & VC Firms (957)
Data sourced from public filings and firms' own websites — see our methodology.










































































